Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 19/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942478 | 0.91 | SCNN1A (0.42) | SCNN1A | |
| SCHEMBL9913762 | 0.86 | SCNN1A (0.69) | SCNN1A | |
| SCHEMBL9913769 | 0.86 | SCNN1A (0.69) | SCNN1A | |
| SCHEMBL14268265 | 0.86 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL17809354 | 0.86 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL2328611 | 0.86 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL9971145 | 0.86 | SCNN1A (0.52) | SCNN1A | |
| Hydrochloric Acid SCHEMBL915536 | 0.86 | SCNN1A (0.51) | SCNN1A | |
| SCHEMBL9913778 | 0.86 | SCNN1A (0.60) | SCNN1A | |
| Hydrochloric Acid SCHEMBL21221602 | 0.86 | SCNN1A (0.68) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2465852-A1 | Capped pyrazinoylguanidine sodium channel blockers | Parion Sciences, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20060205738-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-09-14 | — | — | US | disclosed |
| US-7064129-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1663235-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060052394-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC., DURHAM, NC | 2005-10-20 | — | — | US | disclosed |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005018644-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20060052394-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20060205738-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.